Aravive (NASDAQ:ARAV) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Aravive (NASDAQ:ARAV) released its earnings results on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.04), Fidelity Earnings reports.

NASDAQ ARAV traded up $0.01 during mid-day trading on Friday, reaching $6.53. The stock had a trading volume of 5,300 shares, compared to its average volume of 23,717. Aravive has a 1 year low of $3.07 and a 1 year high of $9.72. The stock has a market cap of $75.95 million, a PE ratio of -0.61 and a beta of 2.17. The company has a fifty day moving average price of $7.03 and a 200 day moving average price of $6.27. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.28 and a quick ratio of 11.28.

ARAV has been the subject of several recent research reports. ValuEngine upgraded shares of Aravive from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Piper Jaffray Companies set a $15.00 target price on shares of Aravive and gave the company a “buy” rating in a report on Friday, September 27th. Zacks Investment Research lowered shares of Aravive from a “buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, HC Wainwright reiterated a “buy” rating on shares of Aravive in a report on Friday. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $13.69.

In related news, CEO Jay Shepard sold 4,004 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $6.82, for a total value of $27,307.28. 39.80% of the stock is owned by insiders.

About Aravive

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

Recommended Story: What are the disadvantages of after-hours trading?

Earnings History for Aravive (NASDAQ:ARAV)

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with's FREE daily email newsletter.

Leave a Reply